Dubai Telegraph - Patients regain much weight after stopping new obesity drug: study

EUR -
AED 3.847595
AFN 70.955217
ALL 98.129555
AMD 407.873345
ANG 1.877009
AOA 956.396496
ARS 1052.049047
AUD 1.610027
AWG 1.888176
AZN 1.778779
BAM 1.955374
BBD 2.102782
BDT 124.452883
BGN 1.956627
BHD 0.394854
BIF 3076.35906
BMD 1.047532
BND 1.403708
BOB 7.23656
BRL 6.114418
BSD 1.041483
BTN 88.395715
BWP 14.228171
BYN 3.408322
BYR 20531.622365
BZD 2.099283
CAD 1.462931
CDF 3007.463637
CHF 0.932508
CLF 0.03692
CLP 1018.737053
CNY 7.590098
CNH 7.59878
COP 4598.402514
CRC 530.489476
CUC 1.047532
CUP 27.759591
CVE 110.855692
CZK 25.335395
DJF 185.46313
DKK 7.457905
DOP 62.766923
DZD 140.965938
EGP 52.004718
ERN 15.712976
ETB 127.496637
FJD 2.382454
FKP 0.826835
GBP 0.833641
GEL 2.870045
GGP 0.826835
GHS 16.546166
GIP 0.826835
GMD 74.374398
GNF 8977.129671
GTQ 8.084076
GYD 219.097457
HKD 8.151698
HNL 26.318517
HRK 7.472315
HTG 136.711517
HUF 411.800971
IDR 16654.445463
ILS 3.862223
IMP 0.826835
INR 88.266649
IQD 1364.328775
IRR 44074.898841
ISK 145.481021
JEP 0.826835
JMD 165.915433
JOD 0.743012
JPY 161.935842
KES 135.658433
KGS 90.613407
KHR 4193.126388
KMF 494.957723
KPW 942.778181
KRW 1468.838686
KWD 0.322504
KYD 0.867927
KZT 520.016622
LAK 22876.452218
LBP 93263.459457
LKR 303.119741
LRD 189.027228
LSL 18.793764
LTL 3.093089
LVL 0.633642
LYD 5.085989
MAD 10.535438
MDL 18.996224
MGA 4861.033639
MKD 61.641022
MMK 3402.342273
MNT 3559.512841
MOP 8.35024
MRU 41.439366
MUR 49.056254
MVR 16.194626
MWK 1805.940983
MXN 21.368218
MYR 4.674611
MZN 66.947912
NAD 18.793764
NGN 1768.715105
NIO 38.322016
NOK 11.58104
NPR 140.650696
NZD 1.79238
OMR 0.403283
PAB 1.04728
PEN 3.94914
PGK 4.193126
PHP 61.827942
PKR 289.212844
PLN 4.334985
PYG 8130.3837
QAR 3.819351
RON 4.976436
RSD 117.00301
RUB 108.876923
RWF 1421.703797
SAR 3.932779
SBD 8.78204
SCR 15.752477
SDG 630.091354
SEK 11.518303
SGD 1.411093
SHP 0.826835
SLE 23.810185
SLL 21966.222062
SOS 595.175999
SRD 37.181136
STD 21681.792335
SVC 9.113188
SYP 2631.954808
SZL 18.787265
THB 36.265313
TJS 11.15323
TMT 3.666361
TND 3.327129
TOP 2.453421
TRY 36.221028
TTD 7.073459
TWD 34.008644
TZS 2775.959214
UAH 43.086435
UGX 3869.619193
USD 1.047532
UYU 44.537316
UZS 13361.088752
VES 48.47434
VND 26633.494828
VUV 124.365075
WST 2.92428
XAF 655.820364
XAG 0.034027
XAU 0.000392
XCD 2.831007
XDR 0.792243
XOF 655.820364
XPF 119.331742
YER 261.804392
ZAR 18.924922
ZMK 9429.03573
ZMW 28.770281
ZWL 337.304797
  • CMSC

    0.0320

    24.672

    +0.13%

  • RBGPF

    59.2400

    59.24

    +100%

  • SCS

    0.2300

    13.27

    +1.73%

  • BCE

    0.0900

    26.77

    +0.34%

  • CMSD

    0.0150

    24.46

    +0.06%

  • GSK

    0.2600

    33.96

    +0.77%

  • BCC

    3.4200

    143.78

    +2.38%

  • BTI

    0.4000

    37.38

    +1.07%

  • RIO

    -0.2200

    62.35

    -0.35%

  • RYCEF

    -0.0100

    6.79

    -0.15%

  • NGG

    1.0296

    63.11

    +1.63%

  • RELX

    0.9900

    46.75

    +2.12%

  • BP

    0.2000

    29.72

    +0.67%

  • AZN

    1.3700

    65.63

    +2.09%

  • JRI

    -0.0200

    13.21

    -0.15%

  • VOD

    0.1323

    8.73

    +1.52%

Patients regain much weight after stopping new obesity drug: study
Patients regain much weight after stopping new obesity drug: study / Photo: Handout - Eli Lilly/AFP/File

Patients regain much weight after stopping new obesity drug: study

A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment.

Text size:

One study published Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs.

The research was based on weekly injections of tirzepatide, the compound in Eli Lilly's new weight loss drug Zepbound that was approved by the United States last month.

After 36 weeks, 670 adults achieved a notable mean weight loss of 20.9 percent.

The group was then split into two, with half continuing on Zepbound, and the other half given a placebo.

At 88 weeks, those on the placebo regained almost half of the weight they had lost, ending up 9.9 percent lower than their baseline.

Those on Zepbound continued to lose weight, ending 25.3 percent lower than where they had started.

The trial patients were mostly women and had a mean age of 48, with a mean weight at the outset was 107.3 kilograms (236.6 pounds).

All participants were encouraged to consume 500 calories less each day than they burnt and take at least 150 minutes of exercise per week.

Common side effects were gastrointestinal issues including nausea, diarrhea, constipation and vomiting, said the study.

- Growing evidence -

Study authors, led by Louis Aronne at Weill Cornell Medicine, New York, said the results "emphasize the need to continue pharmacotherapy to prevent weight regain and ensure the maintenance of weight reduction."

They added the latest research adds to four previous trials that showed "medications, including potent antiobesity medications such as semaglutide, have demonstrated that weight is substantially regained" after stopping treatment.

Semaglutide is the active ingredient in Novo Nordisk's Ozempic and Wegovy, which, like Zepbound, are examples of so-called "GLP-1 agonists" that work by mimicking the function of a hormone that secretes insulin, slows down the emptying of the stomach, and suppresses appetite.

Zepbound also contains another molecule that acts like the gut hormone GIP.

In response to the study, Lilly's Jeff Emmick said in a statement that "patients, providers and the public do not always understand obesity is a chronic disease that often requires ongoing treatment, which can mean that treatment is stopped once weight goals are met."

GLP-1 agonists have been found to cut the risk of cardiovascular disease associated with obesity -- but they also heighten the risk of gastrointestinal problems, studies show.

Though the rates of serious issues such as stomach paralysis are low, some experts fear that using the drugs for years or decades could change the benefit-to-risk calculus.

Cost can also be a disincentive. Zepbound costs $1,059.87 per month, and insurance companies often do not cover weight loss medications. Medicare, state subsidized insurance for the elderly, is barred from covering it.

Y.Chaudhry--DT